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Aims: This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase
subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using
pooled data from 10 phase 3 ODYSSEY trials.
Materials and Methods: Data from 4983 randomized patients (1940 with MetS; 1642 with dia-
betes excluded) were assessed in subgroups by MetS status. Efficacy data were analysed in
4 pools per study design: 2 placebo-controlled pools (1 using alirocumab 150 mg every 2 weeks
[Q2W], 1 using 75/150 mg Q2W) with background statin, and 2 ezetimibe-controlled pools (both
alirocumab 75/150 mg Q2W), 1 with and 1 without background statin. Alirocumab 75/150 mg
indicates possible dose increase from 75 to 150 mg at Week 12 based on Week 8 LDL-C.
Results: LDL-C percentage reduction from baseline at Week 24 with alirocumab was 63.9%
(MetS) and 56.8% (non-MetS) in the pool of alirocumab 150 mg Q2W, and 42.2% to 52.2% (MetS)
and 45.0% to 52.6% (non-MetS) in 3 pools using 75/150 mg Q2W. Levels of other lipid and lipo-
protein parameters were also improved with alirocumab treatment, including apolipoprotein B,
non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein(a) and HDL-C. Overall, the per-
centage change at Week 24 in LDL-C and other lipids and lipoproteins did not vary by MetS status.
Adverse event rates were generally similar between treatment groups, regardless of MetS status;
injection-site reactions occurred more frequently in alirocumab vs control groups.
Conclusions: Across study pools, alirocumab-associated reductions in LDL-C, apolipoprotein B,
and non-HDL-C were significant vs control, and did not vary by MetS status.
KEYWORDS
cardiovascular disease, clinical trial, dyslipidaemia, lipid-lowering therapy
1 | INTRODUCTION
Metabolic syndrome (MetS) is defined by a collection of related meta-
bolic and physiological abnormalities, including central obesity, raised
serum triglycerides (TGs), reduced high-density lipoprotein choles-
terol (HDL-C), glucose intolerance and hypertension.1–3 MetS has
been defined as the presence of 3 or more of the following: elevated
waist circumference (which is assumed in the guidelines if body mass
index [BMI] is >30 kg/m2); TGs ≥150 mg/dL or use of TG-lowering
medication; HDL-C <40 mg/dL in men or <50 mg/dL in women;
blood pressure ≥130/85 mm Hg or diagnosis of hypertension; and
fasting plasma glucose (FPG) ≥100 mg/dL.1 MetS is a common syn-
drome with a rising prevalence worldwide, ranging from approxi-
mately 10% to 80% depending on regional variation and population
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demographics.1,2 MetS is associated with an increased risk of cardio-
vascular (CV) disease (2-fold), type 2 diabetes mellitus (5-fold) and all-
cause mortality (1.5-fold).1,4,5 However, multivariate analyses have
shown that components typically associated with MetS (blood pres-
sure, HDL-C and blood glucose), but not MetS itself, are predictors of
prevalent coronary heart disease.6
While statins are recommended as first-line therapy for reducing
levels of LDL-C, not all patients achieve LDL-C lowering with statin
therapy sufficient to optimally reduce their CV risk. Additionally,
statin intolerance can limit dosage and potency of the statin used,
which is a significant factor in the reduced efficacy of statin therapy
for some patients.7 In particular, patients with MetS may not achieve
non-HDL-C goals following treatment with statins and other lipid-
lowering therapies (LLTs)8 due to elevated TG levels, which are indi-
cators of very-low-density lipoprotein and remnant cholesterol
levels.9 Individuals with MetS typically exhibit mixed dyslipidaemia,
characterised by elevated TGs and lower HDL-C, both of which are
often associated with elevated apolipoprotein (Apo) B and non-HDL-
C levels. In such cases, non-HDL-C or ApoB may give a better esti-
mate of the concentration of atherogenic particles than low-density
lipoprotein cholesterol (LDL-C), and they have been suggested as
alternative treatment targets to LDL-C for such individuals.4
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibi-
tor, has been approved in more than 40 countries, including the USA
and the EU, for reducing elevated LDL-C levels.10,11 Individuals with
metabolic syndrome have a range of clinical and metabolic characteris-
tics that may impact the efficacy and/or safety of a PCSK9 inhibitor,
including obesity, high triglycerides/low HDL-C, high blood glucose
and insulin resistance. For example, PCSK9 appears to have a role in
glucose metabolism and PCSK9 levels have been shown to correlate
with glycaemic parameters and insulin resistance, although evidence is
conflicting among different studies.12,13 Insulin signalling, which is
known to influence LDL-receptor expression (the target of PCSK9), is
often dysregulated in metabolic syndrome.14 However, the use of
PCSK9 inhibitors in individuals with metabolic syndrome is not well
established. In the present study, we compared the efficacy and safety
of alirocumab in patients with hypercholesterolaemia, with or without
MetS, using data from 10 studies from the alirocumab ODYSSEY phase
3 clinical trial programme. This analysis contributes to a better under-
standing of the alirocumab target patient population.
2 | METHODS
2.1 | Study designs and pooling strategy
This analysis includes data from 10 phase 3 ODYSSEY studies
(Figure 1), all of which have been described previously.15–23 Patients
(n = 4983) were randomized to receive alirocumab or control (placebo
or ezetimibe). In 8 of the 10 trials, patients were receiving background
statin therapy, with or without other LLTs. The double-blind treatment
periods ranged between 24 and 104 weeks. In 8 studies, patients
received an initial dose of alirocumab 75 mg every 2 weeks (Q2W),
with a possible dose increase to 150 mg Q2W at Week 12, depending
on LDL-C levels at Week 8 (alirocumab 75/150 mg Q2W); 2 studies
used alirocumab 150 mg Q2W throughout the study. Entry criteria for
the ODYSSEY trials included baseline LDL-C ≥70 mg/dL for those with
prior CV events or ≥100 mg/dL for those without CV events but with
other risk factors. Exceptions were the LONG TERM study (LDL-C
≥70 mg/dL for all patients19), the MONO study (LDL-C 100-190 mg/
dL for all patients21) and the HIGH FH study (LDL-C ≥160 mg/dL for
all patients23). All study protocols were approved by the appropriate
review boards, and all patients provided written, informed consent.
For the current analysis, efficacy data were analysed in 4 pools
according to alirocumab starting dose, control (placebo or ezetimibe)
and use of background statin therapy (yes/no), as shown in Figure 1.
In the first pool (LONG TERM,19 HIGH FH23), patients received aliro-
cumab 150 mg Q2W vs placebo (with statins); in the second
(COMBO I,18 FH I & II15), alirocumab 75/150 mg Q2W vs placebo
(with statins); in the third (COMBO II,17 OPTIONS I & II16,20), alirocu-
mab 75/150 mg Q2W vs ezetimibe (with statins); and in the fourth
(ALTERNATIVE,22 MONO21), alirocumab 75/150 mg Q2W vs ezeti-
mibe (without statins).
Patient baseline characteristics and safety and efficacy data were
further analysed in subgroups, with and without MetS. MetS was
defined in this analysis of the ODYSSEY trials using a definition simi-
lar to that proposed by the International Atherosclerosis Society,24
with 2 important differences. Firstly, waist circumference
FIGURE 1 Overview of ODYSSEY studies
included in this analysis. Abbreviations:
LLT, lipid-lowering therapy; Q2W, every
2 weeks. †Additional non-statin LLTs were
not allowed. Clinicaltrials.gov identifiers:
ALTERNATIVE, NCT01709513; COMBO I,
NCT01644175; COMBO II,
NCT01644188; FH I, NCT01623115; FH
II, NCT01709500; HIGH FH,
NCT01617655; LONG TERM,
NCT01507831; MONO, NCT01644474;
OPTIONS I, NCT01730040; OPTIONS II,
NCT01730053
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measurements were not performed in the alirocumab phase 3 pro-
gram; instead, we used BMI as a proxy, as has been done previ-
ously.25 Second, although 1 of the criteria for the International
Atherosclerosis Society definition was FPG ≥100 mg/dL, which
would include individuals with type 2 diabetes, we introduced a cut-
off of 126 mg/dL for FPG so that individuals with type 2 diabetes
would be excluded. This was to allow examination of the specific
metabolic syndrome population known to be at risk of developing
diabetes and cardiovascular disease. In this analysis, metabolic syn-
drome was defined as the presence of 3 or more of the following:
BMI >30 kg/m2 for non-Asians or >25 kg/m2 for Asians; TGs
≥150 mg/dL or use of TG-lowering medication (which in this analysis
included fibrates); HDL-C <40 mg/dL in men or <50 mg/dL in
women; blood pressure ≥130/85 mm Hg or diagnosis of hyperten-
sion; and FPG ≥100 to <126 mg/dL. Patients with type 1 or type
2 diabetes were excluded from the analysis (type 2 diabetes was
defined based on medical history, or baseline glycated haemoglobin
[HbA1c] ≥6.5%, or 2 FPG values ≥126 mg/dL at screening and ran-
domization). All other patients (ie, those who did not have MetS or
diabetes) were defined as non-MetS for this analysis.
2.2 | Endpoints
The current pooled analysis uses the same efficacy endpoints as the
primary studies. The primary efficacy endpoint in all studies was the
percentage change in LDL-C from baseline to Week 24. LDL-C levels
were calculated using the Friedewald equation if TGs were <400 mg/
dL; in instances above this threshold, LDL-C was determined using
the beta-quantification method. Regardless, LDL-C values derived by
beta-quantification were not included in the efficacy analysis. Sec-
ondary efficacy endpoints included the percentage change from base-
line to Week 24 in other lipids, including non-HDL-C, ApoB,
lipoprotein (a) (Lp[a]), TGs, HDL-C and TG-rich lipoprotein cholesterol
(TRL-C). Non-HDL-C was calculated by subtracting HDL-C from total
cholesterol. The concentration of TRL-C was calculated by subtract-
ing HDL-C and calculated LDL-C from total cholesterol, following the
method of Nordestgaard et al.26 Lp(a) and ApoB levels in serum were
measured from immunonephelometry by a central laboratory
(Medpace Reference Laboratories, Cincinnati, Ohio and Leuven, Bel-
gium, with the exception of the LONG TERM study,19 which used
Covance Central Laboratory, Indianapolis, Indiana). Safety assess-
ments included treatment-emergent adverse events (TEAEs), defined
as events occurring from the time of the first dose of study treatment
to the last dose, plus 70 days. The change over time in glycaemic
parameters (HbA1c and FPG) was also assessed.
2.3 | Statistical analysis
Efficacy data were analysed using an intention-to-treat approach, as
used in the primary trials, where all data were included regardless of
adherence to treatment. The intention-to-treat population included
all randomized participants with an evaluable primary efficacy end-
point (baseline calculated LDL-C value and at least 1 post-baseline
calculated LDL-C value up to Week 24). For most parameters, a
mixed effects model with repeated measures (MMRM) was used toTA
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account for missing data. Least squares means and standard errors
(SE) were taken from the MMRM analysis. For analysis of TGs and
Lp(a), adjusted means and SEs were taken from multiple imputation
followed by robust regression. Interaction P values were calculated
using the same model as above for comparing the difference
(between alirocumab and control) in percent change for lipid end-
points observed in both MetS and non-MetS patients. The proportion
of patients achieving lipid goals was estimated from multiple imputa-
tion using only lipid data from patients who were on-treatment.
3 | RESULTS
3.1 | Patient characteristics
The randomized population for this analysis included 3341 patients
(1940 with MetS; 1401 non-MetS); 1642 randomized individuals with
diabetes were excluded. Baseline characteristics according to alirocu-
mab starting dose, control type and MetS status for each of the 4 pools
are shown in Table 1 and online in Table S1. Patients had a mean age
FIGURE 2 (Continues)
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of 50 to 63 years across the groups; there was a greater proportion of
males than females; and patients were mostly white (>85%). As per the
selection criteria for this analysis, MetS patient groups had higher BMI,
higher systolic blood pressure, a higher percentage of individuals with
hypertension, higher FPG levels, lower levels of HDL-C, and higher
levels of TGs compared to groups without MetS, for both placebo- and
ezetimibe-controlled studies (Table 1). A higher proportion of patients
with MetS were receiving other LLTs in addition to statin (Table S1).
Demographic and baseline characteristics were generally comparable
between the alirocumab and control groups for each pool according to
MetS status. However, for the ezetimibe-controlled studies, patients
without MetS who received alirocumab in the 75/150 mg Q2W (with
statins) pool were more likely to have hypertension (57.8% vs 46.0%)
and atherosclerotic CV disease (90.4% vs 82.0%) than those in the con-
trol group; patients without MetS who received alirocumab in the
75/150 mg Q2W (without statins) pool were more likely to have
FIGURE 2 (Continues)
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atherosclerotic CV disease (23.2% vs 15.7%) and less likely to be
receiving other LLTs (10.0% vs 21.4%).
3.2 | Efficacy
LDL-C percentage reductions from baseline at Week 24 with alirocu-
mab were 63.9% (MetS) and 56.8% (non-MetS) in the pool of alirocu-
mab 150 mg Q2W (interaction P value <.05), 52.2% (MetS) and
45.0% (non-MetS) in the pool of alirocumab 75/150 mg Q2W vs pla-
cebo (interaction P value >.05), 51.9% (MetS) and 52.6% (non-MetS)
in the pool of alirocumab 75/150 mg Q2W vs ezetimibe (with statins)
(interaction P value >.05), and 42.2% (MetS) and 46.7% (non-MetS) in
the alirocumab 75/150 mg Q2W pool (without statins) (interaction
P value >0.05) (Figure 2A).
Across the 4 efficacy pools, by Week 24, alirocumab reduced ApoB
by 35.0% to 55.1% (MetS) and 35.9% to 51.3% (non-MetS) (Figure 2B),
and non-HDL-C by 38.2% to 54.2% (MetS) and 40.0% to 50.0% (non-
MetS) (Figure 2C). ApoB was reduced to a larger extent in the patients
with MetS compared with non-MetS subjects in the alirocumab 75/150
vs placebo pool only at Week 24 (interaction P values <.05) (Figure 2B).
For non-HDL-C, there was no difference in percent reduction from
baseline at Week 24 for those with vs without MetS (Figure 2C). Apart
from LDL-C percent reductions in the alirocumab 150 mg Q2W pool
(interaction P value <.05), there were no differences in LDL-C, ApoB or
non-HDL-C reductions between MetS and non-MetS groups at Week
12 (interaction P values >.05) (Figure S1A-C).
A greater proportion of patients receiving alirocumab achieved
LDL-C and non-HDL-C goals compared with controls at Week
24, regardless of MetS status (Tables S2 and S3).
Across the pools, by Week 24, TGs were reduced by 7.1% to
15.9% (MetS) and 6.5% to 14.9% (non-MetS) (Figure 2D), with similar
results observed at Week 12 (Figure S1D). Lp(a) was reduced by
21.3% to 29.5% (MetS) and 22.7% to 28.8% (non-MetS) at Week
24 (Figure 2E). Reductions in each of these parameters were similar
regardless of MetS status at Week 24 (interaction P values >.05).
At Week 24, the use of other non-statin LLTs did not influence the
percent change from baseline in TG levels observed with alirocumab
(Figure S2); for patients with MetS, the reduction from baseline was
13.3% to 22.6% (with LLT) vs 6.3% to 19.0% (without LLT) and for non-
MetS subjects, the reduction from baseline was 3.2% to 14.7% (with
LLT) vs 0% to 10.0% (without LLT). Non-statin LLTs were examined in
this analysis because of their potential effects on TG levels.
An increase in HDL-C levels of 4.0% to 10.1% was also observed
across the 4 pools following alirocumab therapy at Week 24 (Fig-
ure 2F). HDL-C was increased to a larger extent in the patients with
MetS compared with the non-MetS subjects in the alirocumab
75/150 mg vs placebo pool only (interaction P value <.05); however,
no significant difference between the MetS and non-MetS groups
was observed at Week 12 (interaction P value >.05) (Figure S1E). For
FIGURE 2 Percent change from baseline
in A, calculated LDL-C; B, ApoB; C, non-
HDL-C; D, TGs; E, Lp(a); F, HDL-C and G,
TRL-C at Week 24: Subgroup analysis
according to MetS status at baseline
(intention-to-treat analysis). Abbreviations:
Apo, apolipoprotein; CI, confidence
interval; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein(a); LS, least
squares; MetS, metabolic syndrome; SE,
standard error; TG, triglyceride; TRL-C,
triglyceride-rich lipoprotein cholesterol.
Non-HDL-C was calculated by subtracting
HDL-C from total cholesterol. TRL-C was
calculated by subtracting (HDL-C and
calculated LDL-C) from total cholesterol
FIGURE 3 Time profile of A, mean FPG and B, mean HbA1c levels:
Subgroup analysis according to MetS status for pool of phase
3 studies (safety population). Abbreviations: FPG, fasting plasma
glucose; HbA1c, glycated haemoglobin; MetS, metabolic syndrome;
SD, standard deviation. Figures show combined pools for ezetimibe
and placebo control pools, as differences between alirocumab and
control were similar in both pools. Last value defined as the last value
collected up to 21 days after the last double-blind study treatment
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patients with MetS or non-MetS subjects, the use of non-statin LLTs
at Week 24 did not influence the percent change from baseline in
HDL-C levels observed with alirocumab (Figure S3).
Across the 3 pools with patients on background statin therapy,
alirocumab reduced TRL-C by 2.9% to 12.7% at Week 24, regardless
of MetS status (Figure 2G). In contrast, for alirocumab-treated
patients in the alirocumab 75/150 vs ezetimibe (without statins) pool,
TRL-C was decreased (−4.8%) in patients with MetS and increased
(+1.9%) in subjects without MetS (Figure 2G).
The percentage of patients for whom the alirocumab dose was
increased from 75 to 150 mg Q2W at Week 12 was 36.1% (MetS)
and 32.6% (non-MetS) in the 75/150 mg vs placebo pool, was 17.7%
(MetS) and 15.1% (non-MetS) in the 75/150 mg vs ezetimibe with
statin pool, and was 41.3% (MetS) and 35.0% (non-MetS) in the
75/150 mg vs ezetimibe without statin pool.
3.3 | Safety of alirocumab with respect to patients
by MetS status
Time profiles of mean HbA1c and FPG levels over the treatment
period showed that alirocumab had no clinically meaningful effect on
these parameters compared to control treatments, for patients both
with and without MetS (Figure 3). TEAE rates were generally similar
across all treatment groups, irrespective of MetS status (Table 2). The
most common TEAEs were nasopharyngitis, injection-site reaction,
myalgia and upper respiratory tract infection. Injection-site reactions
occurred more frequently in the alirocumab group vs the control
group, for both placebo-controlled (6.5% vs 6.4% [MetS] and 11.1%
vs 6.1% [non-MetS]) and ezetimibe-controlled (2.7% vs 2.0% [MetS]
and 4.0% vs 1.8% [non-MetS]) trials (Table 2).
4 | DISCUSSION
In this pooled analysis of 10 phase 3 ODYSSEY trials, alirocumab
reduced levels of LDL-C, ApoB, Lp(a), TGs and non-HDL-C in patients
with hypercholesterolaemia, regardless of MetS status. These findings
are important because more than one-third of patients in the ODYS-
SEY trials had MetS (39%). This analysis demonstrated that the typi-
cal characteristics of these patients (mixed dyslipidaemia together
with obesity, glucose intolerance and hypertension, most likely with
additional concomitant medications) did not seem to have a major
impact on the efficacy and safety of alirocumab. A slightly larger reduc-
tion in LDL-C was observed in individuals with MetS (vs no MetS) fol-
lowing alirocumab treatment in 1 of the study pools; however, as this
was not observed in the other pools, it is unclear whether observed
differences are real effects or the result of pooling the post-
randomization groups with relatively small numbers of individuals.
The observed reductions in ApoB and non-HDL-C are of particu-
lar importance, as they may give a better estimate of the concentra-
tion of atherogenic particles than calculated LDL-C for patients with
MetS because of the mixed dyslipidaemia profile.4,24 It is interesting
to note that alirocumab can increase the fractional clearance rates of
non-LDL ApoB 100-containing particles such as intermediate density
lipoprotein and, possibly, Lp(a).27 The moderate reductions in TGs
and moderate increases in HDL-C observed following alirocumab
treatment also demonstrate an improvement in the lipid profile.
Patients with MetS had a higher rate of other LLT use, including
increased fenofibrate, which is often prescribed to reduce TG
levels.28 However, use of non-statin LLTs in combination with aliro-
cumab did not affect the moderate reductions in TGs seen with aliro-
cumab treatment. In addition, the use of non-statin LLTs did not
TABLE 2 Safety analysis (safety population)
% (n)
Placebo-controlled studies Ezetimibe-controlled studies
MetS (n = 1364) Non-MetS (n = 1001) MetS (n = 576) Non-MetS (n = 395)
ALI
(n = 893)
PBO
(n = 471)
ALI
(n = 687)
PBO
(n = 314)
ALI
(n = 329)
EZE
(n = 247)
ALI
(n = 226)
EZE
(n = 169)
TEAEs 77.4 (691) 80.5 (379) 74.8 (514) 75.5 (237) 72.3 (238) 70.4 (174) 69.0 (156) 69.8 (118)
Treatment-emergent SAEs 13.7 (122) 13.6 (64) 11.8 (81) 9.9 (31) 12.2 (40) 12.6 (31) 13.7 (31) 8.9 (15)
TEAEs leading to death 0.3 (3) 0.4 (2) 0.7 (5) 1.3 (4) 0 0.8 (2) 0.4 (1) 1.8 (3)
TEAEs leading to
discontinuations
4.5 (40) 5.3 (25) 4.9 (34) 4.1 (13) 9.7 (32) 8.1 (20) 8.0 (18) 11.2 (19)
TEAEs by preferred term in ≥5% individuals
Nasopharyngitis 12.5 (112) 11.0 (52) 11.9 (82) 14.0 (44) 6.4 (21) 4.5 (11) 6.6 (15) 10.1 (17)
Injection-site reaction 6.5 (58) 6.4 (30) 11.1 (76) 6.1 (19) 2.7 (9) 2.0 (5) 4.0 (9) 1.8 (3)
Myalgia 5.5 (49) 3.8 (18) 4.7 (32) 4.8 (15) 8.5 (28) 8.9 (22) 6.6 (15) 7.7 (13)
Upper respiratory tract
infection
5.4 (48) 6.2 (29) 6.3 (43) 7.0 (22) 7.3 (24) 6.9 (17) 4.9 (11) 3.6 (6)
Influenza 6.9 (62) 4.2 (20) 5.8 (40) 6.4 (20) 3.0 (10) 2.0 (5) 3.5 (8) 2.4 (4)
Headache 4.6 (41) 5.9 (28) 6.4 (44) 5.7 (18) 5.8 (19) 2.8 (7) 3.5 (8) 4.1 (7)
Arthralgia 5.3 (47) 5.9 (28) 4.2 (29) 5.7 (18) 4.6 (15) 4.9 (12) 4.9 (11) 3.0 (5)
Back pain 4.6 (41) 5.9 (28) 4.7 (32) 5.4 (17) 1.8 (6) 3.2 (8) 3.5 (8) 4.7 (8)
Diarrhoea 5.6 (50) 5.7 (27) 4.9 (34) 1.6 (5) 2.7 (9) 1.6 (4) 4.4 (10) 4.7 (8)
Dizziness 3.0 (27) 4.9 (23) 2.6 (18) 2.5 (8) 2.7 (9) 5.7 (14) 4.4 (10) 3.0 (5)
Urinary tract infection 4.8 (43) 3.8 (18) 4.8 (33) 5.1 (16) 2.1 (7) 4.0 (10) 0.9 (2) 2.4 (4)
Abbreviations: ALI, alirocumab; EZE, ezetimibe; PBO, placebo; MetS, metabolic syndrome; SAE, serious adverse event; TEAE, treatment-emergent adverse
event.
HENRY ET AL. 1639
affect the modest increases in HDL-C levels observed with alirocu-
mab treatment.
Previous studies have shown that patients with MetS may not
achieve their non-HDL-C goal following treatment with statins and
other LLTs; in particular, the presence of MetS was shown to be a
factor contributing to a greater difference between recommended vs
attained non-HDL-C levels.8 In the present analysis, a higher propor-
tion of patients receiving alirocumab achieved both LDL-C and non-
HDL-C goals compared with patients receiving placebo or ezetimibe,
irrespective of MetS status.
With regards to safety, MetS status did not affect the incidence of
TEAEs, with similar rates observed between the alirocumab and con-
trol groups. In this analysis, HbA1c and FPG levels were found to be
unaffected by alirocumab in individuals both with and without MetS.
Some studies have suggested that statin therapy is associated with an
increased incidence of type 2 diabetes.29–31 In addition, a Mendelian
randomization study found that PCSK9 and 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase (HMGCR, the target of statin therapy)
genetic variants associated with lower LDL-C were correlated with a
reduced risk of CV events but also an increased risk of diabetes.32
However, the authors emphasize that as PCSK9 antibodies bind extra-
cellular PCSK9, their biological effects may not be the same as those
observed with PCSK9 genetic variants which lower LDL-C levels over
the course of a lifetime.32 Furthermore, a pooled analysis of 10 ODYS-
SEY phase 3 studies, with follow-up periods of between 24 and
104 weeks, indicated that there was no evidence of an effect of aliro-
cumab on the transition to new-onset diabetes in those individuals
without diabetes or with pre-diabetes at baseline.33 Also of note, sub-
group analyses of ODYSSEY trials have shown no effect of diabetes
on the efficacy of alirocumab in terms of LDL-C reduction from base-
line up to Week 104.19,34 Similarly, no effect of pre-diabetes on the
efficacy and safety of alirocumab was observed.35 Lastly, a prespeci-
fied analysis of the FOURIER clinical outcomes study with another
PCSK9 inhibitor, evolocumab, showed no effect of diabetic status on
efficacy and safety with follow-up to 2.2 years, and no effect of evolo-
cumab on the incidence of new-onset diabetes.36
Limitations of this analysis include the relatively short treatment
periods of the ODYSSEY trials and the small number of patients in
some subgroups. Waist circumference, a usual parameter for asses-
sing obesity/MetS, was not measured in the trials. In addition, the
analysis was performed on post-randomization groups, and some dif-
ferences in baseline characteristics between the resulting alirocumab
and control subgroups were noted. In order to provide sufficient
numbers of patients for analysis, data were pooled from studies
including patients with different clinical characteristics (eg, heterozy-
gous familial hypercholesterolaemia,15,23 non-familial hypercholester-
olaemia with prior cardiovascular disease or other risk factors,17,18 or
statin intolerance22), which may limit interpretation of results.
In summary, this pooled analysis showed that alirocumab pro-
duced significant reductions in both LDL-C and non-HDL-C, of similar
magnitudes in individuals both with and without MetS, and was gen-
erally well tolerated, with no apparent effect on measures of glycae-
mic control.
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